Sapiens · Weight

Weight Loss Injections in India: Eligibility, and Who They Are Actually For

Three frameworks shape whether you can be prescribed a weight loss injection in India, and they do not carry the same weight. The product licence defines on-label use: a BMI of 30, or 27 with a weight-related condition. The Endocrine Society of India's 2025 guideline sets the clinical threshold for medicines: 27, or 25 with a condition. And the 2025 Indian obesity consensus adds a staging system that starts obesity at a BMI above 23 and then looks at your waist and your complications. Which of the three your doctor leans on tells you a great deal about how the decision actually gets made, and this page walks through all of them.

The short answer, before the detail: a weight loss injection is a prescription medicine from the GLP-1 family, given once a week (or once a day for the older one), that lowers appetite and slows the stomach. It is meant for adults whose weight is already harming their health, judged by an appropriately qualified prescriber after a proper assessment and blood tests. In the trials that got these medicines licensed, people lost between roughly 8% and 21% of their body weight over a year or more, depending on the molecule and the dose, and most of it came back within a year of stopping. None of that is a reason not to take one. It is the frame you need before you decide.

What is a weight loss injection? Copy link

A weight loss injection is a prescription medicine that copies one or two of the gut hormones your body releases after a meal. The hormone is called GLP-1 (glucagon-like peptide-1), and the medicines are GLP-1 receptor agonists. One of them, tirzepatide, also copies a second hormone, GIP. You inject a small dose under the skin of the abdomen, thigh or upper arm with a pre-filled pen, once a week for semaglutide and tirzepatide, once a day for liraglutide.

What they do is simple to describe. They work on the appetite circuits in your brain, so you feel full sooner and think about food less, and they slow how fast your stomach empties so a meal sits longer. They also help the pancreas release insulin when blood sugar rises, which is why the class was first licensed for type 2 diabetes. The weight loss comes from eating less. Nothing in the medicine "burns fat" directly. The appetite effect is mostly central, in the brain, with the slowed stomach adding to it; nausea comes largely from the gut side, which is why plenty of people lose weight on these medicines without ever feeling sick. You do not need the nausea for the medicine to be working.

They are neither steroids nor stimulants, and they have nothing to do with testosterone or thyroid hormone. That distinction matters in India, where the mental image of "an injection to change your body" still carries the gym-locker associations of something else entirely.

Which weight loss injections are available in India in 2026? Copy link

Three molecules, sold under several brand names, and each product carries its own licence even when the molecule is shared. This trips people up constantly, so it is set out plainly below.

Two things worth saying about that table. First, when Novo Nordisk's semaglutide patent expired on 20 March 2026, a wave of Indian generics launched on the same day, and their licences differ.² Some were approved for diabetes only; others, including 2026 approvals, carry a chronic weight management indication in their own right. So a fair amount of semaglutide used for weight in India is on-label and a fair amount is not, and the only way to know which is to read the specific brand's approved indication. Off-label prescribing is legal and common, but it means the prescriber is taking responsibility for a use the licence does not cover, which is one more reason the decision belongs with an appropriately qualified prescriber. Second, Mounjaro and Yurpeak are the same medicine from the same factory; Cipla distributes the second brand. If a pharmacist offers you one as a substitute for the other, nothing clinical changes.

The individual pages go deeper on each: Mounjaro in India, Wegovy in India, Ozempic in India, and the generic semaglutide brands. If you are trying to choose between the two weekly molecules, Mounjaro vs Wegovy has the head-to-head trial.

Are "fat loss injections", "slimming injections" and B12 shots the same thing? Copy link

No, and this is the confusion that costs people the most money in India. Searches for "fat loss injection" and "slimming injection" land on three unrelated products. One of the three treats obesity.

Lipolytic or "fat-dissolving" injections (deoxycholic acid, phosphatidylcholine, products sold under names like Lipo Lab) are injected into a small area of fat under the skin to break it down locally. Deoxycholic acid has a US licence for one job only, the fat under the chin.³ No regulator anywhere has approved any of these for weight loss, they do nothing to visceral fat, blood sugar or appetite, and the cocktail products sold through aesthetic clinics and online marketplaces in India are not CDSCO-approved for the purpose. They are a cosmetic contouring procedure, at best, for a double chin.

"Vitamin" and "metabolism" shots (B12, L-carnitine, MIC "lipotropic" mixes) have no evidence for weight loss in people who are not deficient. B12 corrects a B12 deficiency. That is all it does.

HCG injections paired with a 500-calorie diet were an Indian slimming-clinic staple for years. The US FDA has stated flatly that HCG is not approved for weight loss and that there is no evidence it produces any; the starvation diet does the losing, and the hormone is theatre.⁴

So when this page, or your doctor, says "weight loss injection", it means the GLP-1 class in the table above. Those are the only injections with large randomised trials, a licence for chronic weight management, and outcome data on heart disease. If a clinic is offering you an injection for weight loss and cannot name the molecule and the trial, that is your cue to ask more questions.

Who are weight loss injections actually for? Copy link

For adults whose excess weight is already affecting their health, or is very likely to, and for whom diet and activity alone have not been enough. That is the principle everyone agrees on. Where the three Indian frameworks differ is in what they are for: the licence defines the product's approved, on-label indication, the ESI guideline tells clinicians when to consider a medicine, and the 2025 consensus stages obesity by adiposity and complications rather than by BMI alone. They sit at different points on the BMI scale, and a good prescriber uses all three.

The label: BMI 30, or 27 with a condition

The Indian product information for tirzepatide, and the international licences for semaglutide and liraglutide, all use the same pair of numbers: obesity at BMI 30 or above, or overweight at BMI 27 or above with at least one weight-related condition such as high blood pressure, dyslipidaemia, type 2 diabetes or sleep apnoea.¹ These are Western thresholds, carried over from the trials, which recruited on them.

The Endocrine Society of India: BMI 27, or 25 with a condition

The ESI's 2025 update to its obesity guideline, published in the Indian Journal of Endocrinology and Metabolism, says pharmacotherapy should be considered at a BMI above 27, or above 25 with a comorbidity, and adds a practical steer: tirzepatide where a 15–20% loss is the target, either tirzepatide or injectable semaglutide where 10–15% will do.⁵

The 2025 Indian obesity consensus: obesity begins above BMI 23

In January 2025, a Delphi consensus led by Anoop Misra at Fortis C-DOC with N-DOC and AIIMS, published as the India Obesity Commission, redefined obesity for Indians living in India in two stages.⁶ It is an expert consensus with wide endorsement, not a government or statutory definition, and it is worth being precise about what it says. Stage 1 means a BMI over 23 with no symptoms from the weight and no obesity-related disease. Stage 2 has a mandatory pair of requirements and then one more. The pair: a BMI over 23 together with abdominal obesity, meaning a waist of 90 cm or more for men, 80 cm for women, or a waist-to-height ratio above 0.5. The one more: either a limitation in daily activity caused by the weight (breathlessness, palpitations, joint pain on ordinary tasks) or an obesity-related condition such as type 2 diabetes, fatty liver, hypertension, sleep apnoea or PCOS. A big waist alone does not make Stage 2. A fatty liver with a normal waist does not either.

The consensus treats Stage 1 as lifestyle-first, with medicines "an option" for a Stage 1 person clearly heading for Stage 2 (a strong family history of diabetes, for instance), for anyone gaining more than 10% despite real effort, or for a BMI of 27.5 or above. At Stage 2 it says drug treatment should start early.⁶ One caveat worth stating plainly: the document was written before Wegovy and Mounjaro were licensed for obesity in India, so its own drug list still names orlistat for people without diabetes and GLP-1 medicines first-line for people with diabetes. Read it for the staging, which is its real contribution, and read the ESI guideline for which medicine.

So which number applies to you?

In practice, most Indian prescribers sit somewhere between the second and third frame. A BMI of 26 with a waist of 96 cm, a fatty liver on ultrasound and an HbA1c of 6.1% is Stage 2 on the consensus and past the ESI threshold, and a person the licence alone would technically exclude. A BMI of 31 with a normal waist, normal sugars, normal liver and no symptoms is a person the label includes and a careful Indian doctor might still counsel to start with three months of structured diet and resistance training first. The number on the scale opens the conversation. What settles it is the waist, the blood tests and what the weight is doing to you.

Frankly, this is also why an online calculator cannot tell you whether you are eligible. It can tell you your BMI, which you can read about on the BMI page, and that is the least decisive of the three inputs.

Why does India use a lower BMI threshold than the West? Copy link

Because at the same BMI, Indians carry more body fat, and more of it around the organs, than people of European ancestry, and develop diabetes and heart disease at lower weights as a result. The cleanest illustration is still the 2004 "Y-Y paradox": two doctors, one Indian and one European, with an identical BMI of 22.3, and body fat of 21.2% in the Indian against 9.1% in the European.^7,8 In the Kerala Diabetes Prevention Program's baseline data, roughly a third of all participants had a normal BMI but a high body-fat percentage, and their rates of diabetes, high blood pressure and abnormal lipids matched those of people with overt obesity.^7,8 Less muscle, more fat, more of it visceral, at any given weight. That is the thin-fat Indian, and it is why a BMI of 24 here is not the reassurance it would be in Manchester.

The scale of the problem is national. The ICMR-INDIAB study, which examined over 113,000 adults across every state and union territory, found generalised obesity on Indian cut-offs in 28.6% of adults and abdominal obesity in 39.5%.⁹ Read those two numbers together: more Indians have a dangerous waist than have a high BMI. That is the whole argument for looking past the BMI.

It is also why the assessment involves a tape measure. If your waist is over 90 cm as a man or 80 cm as a woman, your risk of diabetes, fatty liver and heart disease is materially raised whatever your BMI says, and that is what a weight loss injection is being prescribed to reduce.

Does having PCOS, prediabetes, fatty liver or diabetes change eligibility? Copy link

Usually it makes the case stronger, because these are exactly the weight-related conditions the thresholds are built around. What changes is the work-up before you start, and in some cases which medicine.

Type 2 diabetes. Ozempic, Rybelsus, liraglutide, Mounjaro, Yurpeak and the diabetes-licensed generics are all on-label for it, and the weight loss is a bonus on top of the blood-sugar benefit. If your HbA1c is already in the diabetic range, this is a conversation for your diabetes doctor to lead.

Prediabetes. An HbA1c of 5.7–6.4% or a fasting glucose of 100–125 mg/dL is one of the commonest reasons an Indian doctor moves from "lifestyle first" to "lifestyle plus medicine". In the semaglutide obesity trial, most participants with prediabetes at the start had normal glucose regulation by the end of treatment, though the trial was not designed to test diabetes prevention and the effect was tied to the weight loss itself.¹⁰

Fatty liver. A raised SGPT on your liver function test or fat on an ultrasound counts as a weight-related condition in every Indian framework. Semaglutide 2.4 mg now has phase 3 evidence in the inflammatory form of fatty liver (MASH): in the ESSENCE trial, 62.9% of people on semaglutide had resolution of steatohepatitis without worse fibrosis at 72 weeks, against 34.3% on placebo.²⁰ Whether that steers the choice of molecule for you is a decision for your prescriber; no Indian guideline yet says it should, and tirzepatide produces more weight loss.

PCOS. Insulin resistance and weight gain are central to PCOS, and GLP-1 medicines are used off-label for it with reasonable, smaller-trial evidence. One practical caution specific to tirzepatide: it lowers the absorption of oral contraceptive pills, so the label advises a barrier method for the four weeks following the first dose and each step-up.¹ If you are relying on the pill to manage PCOS or to prevent pregnancy, tell your doctor before you start.

Underactive thyroid. Worth checking, since a high TSH is easy to blame for weight, but the measured effect of treating it on weight is small. Thyroid and weight has the numbers. A thyroid problem neither qualifies nor disqualifies you; it just needs to be treated in parallel.

How much weight do weight loss injections actually take off? Copy link

Less than the headlines and more than any diet, and the range is wide. The figures below are trial averages after roughly a year to 18 months, in adults without diabetes, alongside diet and activity advice. Real-world losses tend to run lower, partly because people miss doses, stop early, or never reach the top dose.

• Liraglutide 3 mg daily: 8.0% of body weight lost against 2.6% on placebo over 56 weeks, in 3,731 adults (SCALE).¹¹
• Semaglutide 2.4 mg weekly: 14.9% against 2.4% over 68 weeks, in 1,961 adults (STEP 1).¹⁰
• Tirzepatide weekly: 15.0% at 5 mg, 19.5% at 10 mg and 20.9% at 15 mg, against 3.1% on placebo, over 72 weeks in 2,539 adults (SURMOUNT-1).¹²

What does 15% mean for you? If you weigh 85 kg, it is about 13 kg over a year and a half, with the fastest loss in the first six months and a plateau after. About a third of people in these trials lost considerably more than the average, and a meaningful minority lost under 5%, which is the level below which the metabolic benefit starts to thin out. Nobody can tell you in advance which group you are in. What is measurable is that even a 5–10% loss improves blood pressure, blood sugar, triglycerides and liver fat, so the benefit does not depend on hitting the trial average.

Two caveats belong right here. First, these were trials in mostly white, mostly female, mostly Western populations; Indian trial participants were a small minority, and there is no large Indian outcomes trial yet, so the numbers are a reasonable guide rather than an Indian guarantee. Second, a portion of the weight lost is muscle. In the DXA sub-studies of these trials, lean tissue made up roughly a quarter of the weight lost on tirzepatide (SURMOUNT-1, 124 treated participants of 160 scanned) and about two-fifths on semaglutide (STEP 1, 95 treated participants).^10,21 Small sub-samples, so hold the exact split loosely. The direction is not in doubt, though, and it is why protein intake and resistance training belong in any competent Indian programme. An older vegetarian adult starting on one of these medicines deserves more attention to that than a 30-year-old.

The one outcome trial worth knowing about is SELECT: in 17,604 adults with existing heart disease and a BMI of 27 or more but no diabetes, semaglutide 2.4 mg cut the rate of heart attack, stroke or cardiovascular death by 20% over about three years.¹³ That is a benefit beyond the scale, and so far it is specific to semaglutide in that population. The like-for-like tirzepatide trial in obesity without diabetes, SURMOUNT-MMO, is still running, so there is no equivalent tirzepatide answer yet.²²

What happens after you stop a weight loss injection? Copy link

Most of the weight comes back, and the trials measured how much. In the STEP 1 extension, people who stopped semaglutide after 68 weeks had regained two-thirds of what they lost within a year of stopping.¹⁴ In SURMOUNT-4, people switched from tirzepatide to placebo after 36 weeks regained 14% of their body weight over the following year, while those who continued lost a further 5.5%.¹⁵ Blood pressure, sugars and lipids drifted back with the weight.

This is the single fact most people are not told before they start, and it changes what you are agreeing to. The WHO's December 2025 guideline describes these medicines as long-term treatment for a chronic, relapsing disease, to be used with intensive behavioural support, and both of its recommendations are conditional rather than strong, partly because long-term data past a few years do not yet exist.¹⁶ In plain terms: you are not buying a course. You are starting a management plan that includes a strategy for what happens when the dose comes down, and that strategy is protein, strength training, sleep and follow-up, put in place while you are still on the medicine.

Does everyone regain? No. A minority hold most of the loss, and they tend to be the people who used the medicated year to change how they eat and train. Stopping is something to plan with your doctor, and never something to do abruptly because a pen ran out before a wedding.

Who should not take a weight loss injection? Copy link

Two lists, and they are different in kind. The first is people for whom the product label in question says no. The second is people who can sometimes be treated, but only after a specialist has weighed it, and with closer follow-up than usual. Labels are not identical across brands or countries, so the first list is shorter, and more brand-specific, than the US-label version that circulates online.

Do not use

• Whatever the specific Indian product information lists. Contraindications differ by product and by market, and your prescriber should check the current Indian prescribing information for the exact brand. The clearest example is the thyroid warning: all GLP-1 medicines caused thyroid C-cell tumours in rodents, and the US labels turn that into a contraindication where medullary thyroid cancer or multiple endocrine neoplasia type 2 runs in the patient or the family. The Indian Wegovy prescribing information does not: it lists hypersensitivity as the only contraindication, records the rodent finding under non-clinical data and calls its relevance to humans "low, but cannot be completely excluded".¹⁷ Other Indian brands may word this differently. If that history is in your family, say so, and let the prescriber read the label for the brand in front of you.
• A serious allergic reaction to the molecule or any component of the pen.
• Pregnancy, and trying to conceive. Weight-management treatment is stopped for pregnancy; semaglutide should be stopped at least two months before a planned pregnancy because it clears slowly.¹⁷ If you are a woman in your late twenties or thirties starting a weight loss injection in India, this deserves an explicit conversation, because it is common to plan a pregnancy within the treatment window. Breastfeeding is also a reason to hold off.

Needs specialist judgement and extra care

• A history of pancreatitis. Often a reason not to prescribe; where treatment goes ahead, any severe abdominal pain means stopping and being assessed the same day.
• Type 1 diabetes, or a history of diabetic ketoacidosis. Not licensed for weight management here, and not something to start without an endocrinologist.
• Insulin or a sulfonylurea already on board. Both raise the risk of low blood sugar when a GLP-1 medicine is added; doses usually need adjusting.
• Diabetic eye disease. A rapid improvement in blood sugar can temporarily worsen existing retinopathy, so a retinal check first is sensible if you have diabetes.
• Severe gut disease such as gastroparesis or a history of bowel obstruction, because the medicines slow the gut further.
• Gallstones or gallbladder disease. Rapid weight loss on these medicines raises gallstone risk; existing stones need discussing.
• Reduced kidney function. The medicines themselves are not toxic to kidneys, but severe vomiting and dehydration in the first weeks can tip a vulnerable kidney over; extra monitoring and a clear plan for fluids matter.
• An eating disorder, past or present. A medicine that removes appetite is dangerous in anorexia or bulimia, and a prescriber who does not ask about this before prescribing is not doing the job.
• Under 18. Semaglutide has an adolescent licence in some countries; in India, prescribing to teenagers is specialist territory.

Beyond both lists there is a group for whom the medicine is simply the wrong tool: people at a healthy weight who want to lose five kilos before an event. The medicines are licensed to treat a disease. Used for that, in someone who does not have it, the side effects are the same and the benefit is nil.

One eye risk has moved from "under review" to settled. In June 2025 the European Medicines Agency's safety committee concluded that NAION, a form of sudden optic-nerve damage, is a very rare adverse effect of semaglutide, affecting up to 1 in 10,000 users, roughly one extra case per 10,000 person-years, and the WHO issued its own communication three weeks later.^23,24 Sudden loss or blurring of vision in one eye on semaglutide means stopping and being seen urgently. The side effects page covers the full picture.

What does a doctor check before prescribing a weight loss injection? Copy link

A proper assessment takes about an hour and has four parts. A form on a phone is a different thing.

Measurements. Weight, height, BMI, and a waist measurement taken standing, at the end of a normal breath, just above the hip bone. Blood pressure. Some clinics add a body-composition scan; it is useful for tracking muscle but not essential for the decision.

History. How long the weight has been there and what has been tried. Family history of diabetes, heart disease and thyroid cancer. Every medicine you take, including the ones you would not think to mention, such as an oral contraceptive, insulin or a sulfonylurea (the last two raise hypoglycaemia risk when combined). Whether you are planning a pregnancy. Whether you have ever had pancreatitis, gallstones or an eating disorder. How much you drink.

Baseline blood tests. There is no single mandated panel, but a sensible Indian baseline covers fasting glucose and HbA1c, a lipid profile, liver enzymes, kidney function, thyroid function, and often vitamin B12 and D. Their purpose is twofold: to confirm the medicine is safe to start, and to find what the weight has already done, since a fatty liver or a prediabetic HbA1c changes the urgency of treatment. The GLP-1 blood tests page explains what each result means for the plan. If you have not had bloods in a year, a full body checkup covers most of it.

Expectations. Good doctors spend the longest on this. What loss is realistic for you, at what pace, with what side effects in the first eight weeks, how the dose will be stepped up, what the protein target is, how often you will be reviewed, and what the plan is at twelve months. If you leave a consultation with a prescription and none of that, you have been sold a pen.

That assessment, with follow-up built in, is what a doctor-led programme is for. An appropriately qualified prescriber can review your history, your Indian-threshold measurements and your baseline results together and tell you whether a weight loss injection is the right tool for you, or whether something else comes first.

What do weight loss injections cost in India? Copy link

From roughly ₹1,300 a month for the lowest-dose generic semaglutide to ₹25,781 a month for 15 mg tirzepatide, at listed maximum retail prices checked on 26 August 2026, before any retailer discount.^25,26 Prices in this category have moved sharply twice in the past year, once when Wegovy's prices were cut in March 2026 and again when generic semaglutide launched, so treat any figure older than a few months as stale. The drug is also only one of four costs: consultations, baseline and follow-up blood tests, and early anti-nausea medicine are the others. Weight loss treatment in India keeps the current price table, and the GLP-1 medications guide compares the brands dose by dose.

Can you buy a weight loss injection without a prescription in India? Copy link

Not lawfully. Every GLP-1 medicine sold in India needs a prescription, and the government has gone further than the usual prescription rule: the class was approved with a condition that it be prescribed by endocrinologists and internal medicine specialists, and for some indications cardiologists, according to the approved indications.^18,19 On 10 March 2026 the Central Drugs Standard Control Organisation issued an advisory to manufacturers and marketers: prescription medicines including GLP-1 receptor agonists must be prescribed by registered medical practitioners as per their approved indications. The same advisory prohibited surrogate advertising and any promotion, "awareness" campaigns and digital outreach included, that encourages their use without medical supervision. A second advisory on 27 March asked every state drug controller to police the supply chain.¹⁸ The WHO's December 2025 guidance flags the parallel problem: global demand has produced falsified and substandard GLP-1 products, and a prescription filled through a regulated pharmacy is the only reliable protection.¹⁶

The practical translation for India: dispensing these medicines without the required prescription is unlawful, and unregulated channels (a marketplace listing, an Instagram clinic, a gym contact) also carry a real risk of counterfeit or substandard product. A falsified pen may contain nothing, or insulin, which in a non-diabetic can be fatal. If the price is far below the listed MRP and nobody has asked you a single medical question, walk away.

Where this leaves you Copy link

If your BMI is above 23, your waist is over 90 cm (men) or 80 cm (women), and you already have prediabetes, fatty liver, PCOS, high blood pressure or sleep apnoea, or the weight is limiting what you can do, and your own efforts have stalled, you are a candidate for the conversation. Not for the pen, yet. For the conversation. A weight loss injection can take 10–20% of your body weight off over a year and improve nearly every metabolic number on your report, and it will give most of that back if it is stopped without a plan. Whether it is right for you is a decision made on your waist, your bloods and your history, by a qualified prescriber who will still be there at month six. Start there.

This article is educational and does not replace personalised medical advice. GLP-1 weight loss injections are prescription-only in India: do not start, stop or change treatment without a qualified prescriber. Prices move; verify the printed MRP at purchase. Report an error on this page.